Twenty year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA syndrome

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • M. Kanariou - , Agia Sofia Children's Hospital, Athens (Author)
  • C. Dracou - , Children's Hospital Panagiotis and Aglaia Kyriakou (Author)
  • K. Spanou - , Agia Sofia Children's Hospital, Athens (Author)
  • J. Möller - (Author)
  • A. Rösen-Wolff - , Department of Paediatrics (Author)
  • V. Schuster - (Author)
  • J. Roesler - (Author)

Abstract

We report on a 22-year-old girl with a history of recurrent febrile episodes, chronic arthritis, urticarial rash, and neurological symptoms including right hemiparesis, internal hydrocephalus, mental retardation, progressive deafness, and visual impairment. Treatment starting at age 20 months, including different combinations of immunosuppressive and antiinflammatory drugs such as corticosteroids and anti-TNFα antibody, was unsuccessful. Four years ago, we found a heterozygous S595G mutation in the NLRP3 gene of this patient. This prompted us to introduce anakinra, which resulted in considerable improvement of the patient's complaints.

Details

Original languageEnglish
Pages (from-to)379-381
Number of pages3
JournalKlinische Pädiatrie : clinical research and practice in pediatrics
Volume221
Issue number6
Publication statusPublished - 2009
Peer-reviewedYes

External IDs

Scopus 77449105314

Keywords

Keywords

  • autoinflammation, amyloidosis, urticarial rash, hydrocephalus, Autoinflammation, Amyloidose, Urtikaria, Hydrozephalus